MediPharm Labs Corp. (LABS.TO)

CAD 0.06

(-7.69%)

Net Debt Summary of MediPharm Labs Corp.

MediPharm Labs Corp.'s latest annual net debt in 2023 was -15.68 Million CAD , up 33.29% from previous year.
MediPharm Labs Corp.'s latest quarterly net debt in 2024 Q2 was -13.18 Million CAD , up 11.01% from previous quarter.
MediPharm Labs Corp. reported annual net debt of -23.51 Million CAD in 2022, up 30.63% from previous year.
MediPharm Labs Corp. reported annual net debt of -33.89 Million CAD in 2021, down -2229.48% from previous year.
MediPharm Labs Corp. reported quarterly net debt of -13.18 Million CAD for 2024 Q2, up 11.01% from previous quarter.
MediPharm Labs Corp. reported quarterly net debt of -15.68 Million CAD for 2023 Q4, down -53.33% from previous quarter.

Annual Net Debt Chart of MediPharm Labs Corp. (2023 - 2016)

Historical Annual Net Debt of MediPharm Labs Corp. (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	-15.68 Million CAD	33.29%
2022	-23.51 Million CAD	30.63%
2021	-33.89 Million CAD	-2229.48%
2020	-1.45 Million CAD	94.81%
2019	-28.04 Million CAD	-1416.05%
2018	-1.85 Million CAD	-327.55%
2017	813 Thousand CAD	442.57%
2016	-237.32 Thousand CAD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-14.81 Million CAD	5.58%
2024 Q2	-13.18 Million CAD	11.01%
2023 Q4	-15.68 Million CAD	-53.33%
2023 FY	-15.68 Million CAD	33.29%
2023 Q2	-11.83 Million CAD	40.65%
2023 Q1	-19.93 Million CAD	15.23%
2023 Q3	-10.23 Million CAD	13.52%
2022 Q2	-20.54 Million CAD	26.92%
2022 Q4	-23.51 Million CAD	-28.59%
2022 FY	-23.51 Million CAD	30.63%
2022 Q1	-28.11 Million CAD	17.04%
2022 Q3	-18.28 Million CAD	11.01%
2021 Q1	-38.57 Million CAD	-2551.27%
2021 FY	-33.89 Million CAD	-2229.48%
2021 Q4	-33.89 Million CAD	5.07%
2021 Q3	-35.7 Million CAD	2.59%
2021 Q2	-36.65 Million CAD	4.98%
2020 FY	-1.45 Million CAD	94.81%
2020 Q1	-11.1 Million CAD	60.39%
2020 Q2	-11.65 Million CAD	-4.93%
2020 Q3	-5.07 Million CAD	56.51%
2020 Q4	-1.45 Million CAD	71.3%
2019 Q2	-66.72 Million CAD	-2680.13%
2019 FY	-28.04 Million CAD	-1416.05%
2019 Q4	-28.04 Million CAD	20.48%
2019 Q3	-35.27 Million CAD	47.14%
2019 Q1	-2.4 Million CAD	-29.73%
2018 Q3	1.53 Million CAD	12.74%
2018 FY	-1.85 Million CAD	-327.55%
2018 Q1	-520.48 Thousand CAD	-161.16%
2018 Q2	1.36 Million CAD	361.68%
2018 Q4	-1.85 Million CAD	-220.48%
2017 FY	813 Thousand CAD	442.57%
2017 Q4	850.95 Thousand CAD	312.74%
2017 Q3	-400 Thousand CAD	0.0%
2017 Q1	262.18 Thousand CAD	0.0%
2016 FY	-237.32 Thousand CAD	0.0%

Peer Net Debt Comparison of MediPharm Labs Corp.

Name	Net Debt	Net Debt Difference
Aurora Cannabis Inc.	-8.64 Million CAD	-81.383%
Avicanna Inc.	1.32 Million CAD	1282.779%
Avant Brands Inc.	17.93 Million CAD	187.485%
Cardiol Therapeutics Inc.	-34.77 Million CAD	54.891%
Crescita Therapeutics Inc.	-8.13 Million CAD	-92.916%
Knight Therapeutics Inc.	10.33 Million CAD	251.849%
OrganiGram Holdings Inc.	-33.7 Million CAD	53.466%
Canopy Growth Corporation	512.87 Million CAD	103.058%
Willow Biosciences Inc.	-989 Thousand CAD	-1486.047%
Auxly Cannabis Group Inc.	142.88 Million CAD	110.978%